**Mark Murcko, Ph.D.**

*Chief Scientific Officer and Board Member*

Mark Murcko was an early leader in structure-based drug design and has directly contributed to seven marketed drugs spanning HIV, cystic fibrosis, and glaucoma. He is a Founder, Board member, and was the interim CSO at Relay Therapeutics. In addition, Mark is a senior lecturer in the Department of Biological Engineering at MIT, and has served on numerous scientific advisory boards and corporate boards of directors for a diverse range of organizations. Mark was chief technology officer and chair of the SAB of Vertex Pharmaceuticals and was responsible for the identification, validation and implementation of disruptive technologies across R&D. Mark is a co-inventor of the HCV protease inhibitor Incivek (telaprevir), as well as Agenerase (amprenavir) and Lexiva (fosamprenavir), Vertex’s two marketed drugs for the treatment of HIV. In addition, he guided the early efforts of Vertex’s cystic fibrosis program that later produced the marketed drugs Kalydeco (ivacaftor) and Orkambi (lumacaftor / ivacaftor). He also led the early stages of Vertex's influenza program which lead to pimodivir, currently in Phase 3 trials.

Prior to Vertex, Mark worked at Merck Sharpe & Dohme, where he helped discover multiple clinical candidates, including inhibitors of the enzyme carbonic anhydrase for the treatment of glaucoma. He chaired the 2013 Gordon Research Conference in Medicinal Chemistry and is currently a member of the Board of Trustees of the GRC. He is a co-inventor on more than 50 issued and pending patents and has co-authored more than 85 scientific articles. Mark holds a Ph.D. in organic chemistry from Yale University.

**Bruce Beutel, Ph.D.**

*Chief Operating Officer*

Bruce Beutel has over 25 years of leadership experience in drug discovery and business development,having led large research teams in a variety of therapeutic and technology areas at both large and small companies. He joined Dewpoint as the founding chief operating officer in 2018 and is an entrepreneur in residence at the LS Polaris Innovation Fund. His work has resulted in the invention of novel drug discovery technologies and several first-in-class molecules entering clinical trials, and he has led deal teams to close numerous significant biotech-pharma licensing and collaboration deals.

Bruce’s prior roles included chief business officer at SQZ Biotechnologies, executive director at Merck, chief scientific officer at Znomics, and senior director at Abbott Laboratories. He has over 30 peer-reviewed publications and seven issued patents. He received his BA in Biology from the University of Chicago and his PhD in Molecular Biology from the University of Wisconsin-Madison.

**Stephen Hale, Ph.D.**

*Senior Vice President of Discovery Biology*

Steve Hale has advanced programs across cardiovascular, oncology, immunology, and neurodegeneration in his 20+ years in drug discovery. He is co-inventor of a transformative DNA-Encoded Library (DEL) and screening technology that has since become ubiquitous in the industry as the gold-standard for encoded-small-molecule discovery. Prior to joint Dewpoint, he worked as a consultant and entrepreneur advising over 10 emerging and established companies. Previously, Steve was CSO of Ensemble Therapeutics, where he built a drug discovery platform supporting six major collaborations that raised over $80M in non-dilutive capital. At Ensemble he was responsible for initiating and advancing internal and partnered programs that leveraged DNA-encoded macrocyclic compound collections and a massively parallel screening process.

Before joining Ensemble, Steve was at Praecis Pharmaceuticals, where he helped advance oncology programs, including Plenaxis, approved for prostate cancer prior to an acquisition by GSK. He joined Praecis from Phylos (Adnexus/BMS), a therapeutics discovery and development company where he was a founding scientist. Steve received his bachelors in biochemistry from the University of New Hampshire and doctorate from University of Maryland in chemical biology, followed by an NIH postdoctoral fellowship at MIT under Paul Schimmel that focused on understanding the therapeutic implications of specific protein:RNA interactions.